2Tedder M,Spratt JA,Anstadt MP,Hegde SS,Tedder SD,Lowe JE.Pulmonary mucormycosis:results of medical and surgical therapy.Ann Thorac Surg,1994,57:1044-1050.
3Lee FY,Mossad SB,Adal KA.Pulmonary mucormycosis:the last 30 years.Arch Intern Med,1999,159:1301-1309.
4Abraham P,Govil S,Srivastava VM,Ganesh A.Sponta-neous regression of pulmonary mucormycosis.Postgrad Med J,1995,71:632 -634.
5Pagano L,Ricci P,Tonso A,et al.Mucormycosis in patients with haematological malignancies:a retrospective clinical study of 37 cases.Br J Haematol 1997 ;99:331-336.
7Gomez Lopez A,Cuenca Estrella M,Monzon A,Rodri gnez-Tudela JL.In vitro susceptibilities of clinical isolates of zygomycota to amphotericin B,flucytosine,itracon-azole,and voriconazole.J Antimicrob Chemother,2001,48:919 -921.
8Jose R.Donado Unaa:Persistent cavitations in pulmonary mucormycosis after apparently successful amphotericin B; European Journal of Cardiothoracic Surgery,2002,21:940-942.
9Louie,A,Banerjee P,Drusano GL.et al.Interaction between flucon-azole and amphotericin B in mice with systemic infection due to flucon-azole susceptible or resistant strains of Candida albicans.Antimicrobial Agents and Chemotherapy,1999,43:2841-4847.
10Rodero L,Cordoba S,Cahn P,et al.In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.Journal of Antimicrobial Chemotherapy,2000,45:239-242.
